Genetically modified dendritic cells prime autoreactive t cells through a pathway independent of CD40l and interleukin 12: Implications for cancer vaccines

Cancer Research

Volumn 60, Issue 12, 2000, Pages 3247-3253

  Wan, Yonghong ^a   Bramson, Jonathan ^a   Pilon, Andrew ^a   Zhu, Qing ^a   Gauldie, Jack ^a  

^a MCMASTER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; GAMMA INTERFERON; GLYCOPROTEIN GP 39; INTERLEUKIN 12; MELANOMA ANTIGEN;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DENDRITIC CELL; IMMUNIZATION; MELANOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE; TUMOR IMMUNITY; TUMOR REJECTION; VIRUS EXPRESSION;

ADENOVIRIDAE; ANIMALS; AUTOIMMUNITY; CANCER VACCINES; CD4-POSITIVE T-LYMPHOCYTES; CD40 LIGAND; CD8-POSITIVE T-LYMPHOCYTES; DENDRITIC CELLS; GENETIC VECTORS; HUMANS; INTERFERON TYPE II; INTERLEUKIN-12; KILLER CELLS, NATURAL; MELANOMA, EXPERIMENTAL; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; PHENOTYPE; SPLEEN; T-LYMPHOCYTES; T-LYMPHOCYTES, CYTOTOXIC; TIME FACTORS;

EID: 0034095604     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (51)

1. Boon, T., Cerottini, J. C., Van den Eynde, E., van der Bruggen, P., and Van Pel, A. Tumor antigens recognized by T lymphocytes. Annu. Rev. Immunol., 12: 337-365, 1994.
2. Rosenberg, S. A. Cancer vaccines based on the identification of genes encoding cancer regression antigens. Immunol. Today, 18: 175-182, 1997.
3. Houghton, A. N. Cancer antigens: immune recognition of self and altered self. J. Exp. Med., 180: 1-4, 1994.
4. Nanda, N. K., and Sercarz, E. E. Induction of anti-self-immunity to cure cancer. Cell, 82: 13-17, 1995.
5. Pardoll, D. M. Inducing autoimmune disease to treat cancer. Proc. Natl. Acad. Sci. USA, 96: 5340-5342, 1999.
6. Dyall, R., Bowne, W. B., Weber, L. W., LeMaoult, J., Szabo, P., Moroi, Y., Piskun, G., Lewis, J. J., Houghton, A. N., and Nikolic-Zugic, J. Heteroclitic immunization induces tumor immunity. J. Exp. Med., 188: 1553-1561, 1998.
7. Weber, L. W., Bowne, W. B., Wolchok, J. D., Srinivasan, R., Qin, J., Moroi, Y., Clynes, R., Song, P., Lewis, J. J., and Houghton, A. N. Tumor immunity and autoimmunity induced by immunization with homologous DNA. J. Clin. Investig., 102: 1258-1264, 1998.
8. Overwijk, W. W., Tsung, A., Irvine, K. R., Parkhurst, M. R., Goletz, T. J., Tsung, K., Carroll, M. W., Liu, C., Moss, B., Rosenberg, S. A., and Restifo, N. P. gp100/pmel 17 is a murine tumor rejection antigen: induction of "self"-reactive, tumoricidal T cells using high-affinity, altered peptide ligand. J. Exp. Med., 188: 277-286, 1998.
9. Disis, M. L., Shiota, F. M., and Cheever, M. A. Human HER-2/neu protein immunization circumvents tolerance to rat neu: a vaccine strategy for 'self' tumour antigens. Immunology, 93: 192-199, 1998.
10. Zhai, Y., Yang, J. C., Kawakami, Y., Spiess, P., Wadsworth, S. C., Cardoza, L. M., Couture, L. A., Smith, A. E., and Rosenberg, S. A. Antigen-specific tumor vaccines. Development and characterization of recombinant adenoviruses encoding MART1 or gp100 for cancer therapy. J. Immunol., 156: 700-710, 1996.
11. Schreurs, M. W., de Boer, A. J., Figdor, C. G., and Adema, G. J. Genetic vaccination against the melanocyte lineage-specific antigen gp100 induces cytotoxic T lymphocyte-mediated tumor protection. Cancer Res., 58: 2509-2514, 1998.
12. Zhou, W. Z., Kaneda, Y., Huang, S., Morishita, R., and Hoon, D. Protective immunization against melanoma by gp100 DNA-HVJ-liposome vaccine. Gene Ther., 6: 1768-1773, 1999.
13. + T-cell responses and are more effective than DNA vaccines at generating anti-tumor immunity. Int. J. Cancer, 83: 532-540, 1999.
14. Wan, Y. H., Emtage, P., Zhu, Q., Foley, R., Pilon, A., Roberts, B., and Gauldie, J. Enhanced immune response to the melanoma antigen gp100 using recombinant adenovirus-transduced dendritic cells. Cell. Immunol., 198: 131-138, 2000.
15. Kaplan, J. M., Yu, Q., Piraino, S. T., Pennington, S. E., Shankara, S., Woodworth, L. A., and Roberts, B. L. Induction of antitumor immunity with dendritic cells transduced with adenovirus vector-encoding endogenous tumor-associated antigens. J. Immunol., 163: 699-707, 1999.
16. + T cell responses in antitumor immunity. Curr. Opin. Immunol., 10: 588-594, 1998.
17. Toes, R. E., Ossendorp, F., Offringa, R., and Melief, C. J. CD4 T cells and their role in antitumor immune responses. J. Exp. Med., 189: 753-756, 1999.
18. + T cells eliminate MHC class II-negative cancer cells in vivo by indirect effects of IFN-γ. Proc. Natl. Acad. Sci. USA, 96: 8633-8638, 1999.
19. Ossendorp, F., Mengede, E., Camps, M., Filius, R., and Melief, C. J. Specific T helper cell requirement for optimal induction of cytotoxic T lymphocytes against major histocompatibility complex class II negative tumors. J. Exp. Med., 187: 693-702, 1998.
20. Schoenberger, S. P., Toes, R. E., van der Voort, E. I., Offringa, R., and Melief, C. J. T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. Nature (Lond.), 393: 480-483, 1998.
21. + T-helper and a T-killer cell. Nature (Lond.), 393: 474-478, 1998.
22. Bennett, S. R., Carbone, F. R., Karamalis, F., Flavell, R. A., Miller, J. F., and Heath, W. R. Help for cytotoxic-T-cell responses is mediated by CD40 signaling. Nature (Lond.), 393: 478-480, 1998.
23. Whitmire, J. K., Flavell, R. A., Grewal, I. S., Larsen, C. P., Pearson, T. C., and Ahmed, R. CD40-CD40 ligand costimulation is required for generating antiviral CD4 T cell responses but is dispensable for CD8 T cell responses. J. Immunol., 163: 3194-3201, 1999.
24. + T-cell tolerance to T-cell priming through in vivo ligation of CD40. Nat. Med., 5: 780-787, 1999.
25. Kaplan, J. M., Armentano, D., Sparer, T. E., Wynn, S. G., Peterson, P. A., Wadsworth, S. C., Couture, K. K., Pennington, S. E., St. George, J. A., Gooding, L. R., and Smith, A. E. Characterization of factors involved in modulating persistence of transgene expression from recombinant adenovirus in the mouse lung. Hum. Gene Ther., 8: 45-56, 1997.
26. Hitt, M., Bett, A. J., Prevec, L., and Graham, F. L. Construction and propagation of human adenovirus vectors. In: J. E. Celis (ed.), Cell Biology: A Laboratory Handbook, pp. 500-512. San Diego, CA: Academic Press, 1998.
27. Cayeux, S., Richter, G., Becker, C., Pezzutto, A., Dorken, B., and Blankenstein, T. Direct and indirect T cell priming by dendritic cell vaccines. Eur. J. Immunol., 29: 225-234, 1999.
28. Kawano, T., Cui, J., Koezuka, Y., Toura, I., Kaneko, Y., Motoki, K., Ueno, H., Nakagawa, R., Sato, H., Kondo, E., Koseki, H., and Taniguchi, M. CD1d-restricted and TCR-mediated activation of vα14 NKT cells by glycosylceramides. Science (Washington DC), 278: 1626-1629, 1997.
29. Cui, J., Shin, T., Kawano, T., Sato, H., Kondo, E., Toura, I., Kaneko, Y., Koseki, H., Kanno, M., and Taniguchi, M. Requirement for Vα14 NKT cells in IL-12-mediated rejection of tumors. Science (Washington DC), 278: 1623-1626, 1997.
30. Smiley, S. T., Kaplan, M. H., and Grusby, M. J. Immunoglobulin E production in the absence of interleukin-4-secreting CD1-dependent cells. Science (Washington DC), 275: 977-979, 1997.
31. Schofield, L., McConville, M. J., Hansen, D., Campbell, A. S., Fraser-Reid, B., Grusby, M. J., and Tachado, S. D. CD1d-restricted immunoglobulin G formation to GPI-anchored antigens mediated by NKT cells. Science (Washington DC), 283: 225-229, 1999.
32. + T cells through IL-12 produced by Listeria-induced macrophages. Science (Washington DC), 260: 547-549, 1993.
33. Bianchi, R., Grohmann, U., Vacca, C., Belladonna, M. L., Fioretti, M. C., and Puccetti, P. Autocrine IL-12 is involved in dendritic cell modulation via CD40 ligation. J. Immunol., 163: 2517-2521, 1999.
34. Magram, J., Connaughton, S. E., Warrier, R. R., Carvajal, D. M., Wu, C. Y., Ferrante, J., Stewart, C., Sarmiento, U., Faherty, D. A., and Gately, M. K. IL-12-deficient mice are defective in TFN γ production and type 1 cytokine responses. Immunity, 4: 471-481, 1996.
35. Li, Y., Li, X. C., Zheng, X. X., Wells, A. D., Turka, L. A., and Strom, T. B. Blocking both signal 1 and signal 2 of T-cell activation prevents apoptosis of alloreactive T cells and induction of peripheral allograft tolerance. Nat. Med., 5: 1298-1302, 1999.
36. Kirk, A. D., Burkly, L. C., Batty, D. S., Baumgartner, R. E., Berning, J. D., Buchanan, K., Fechner, J. H., Jr., Germond, R. L., Kampen, R. L., Patterson, N. B., Swanson, S. J., Tadaki, D. K., TenHoor, C. N., While, L., Knechtle, S. J., and Harlan, D. M. Treatment with humanized monoclonal antibody against CD154 prevents acute renal allograft rejection in nonhuman primates. Nat. Med., 5: 686-693, 1999.
37. Grewal, I. S., Borrow, P., Pamer, E. G., Oldstone, M. B., and Flavell, R. A. The CD40-CD154 system in anti-infective host defense. Curr. Opin. Immunol., 9: 491-497, 1997.
38. Diehl, L., den Boer, A. T., Schoenberger, S. P., van der Voort, E. L., Schumacher, T. N., Melief, C. J., Offringa, R., and Toes, R. E. CD40 activation in vivo overcomes peptide-induced peripheral cytotoxic T-lymphocyte tolerance and augments anti-tumor vaccine efficacy. Nat. Med., 5: 774-779, 1999.
39. + T cells in the antitumor immune response. J. Exp. Med., 188: 2357-2368, 1998.
40. - T cells: tumor eradication does not require participation of cytotoxic T cells. J. Exp. Med., 161: 1122-1134, 1985.
41. + T lymphocytes. Proc. Natl. Acad. Sci. USA, 96: 2982-2987, 1999.
42. Sigal, L. J., Crotty, S., Andino, R., and Rock, K. L. Cytotoxic T-cell immunity to virus-infected non-haematopoietic cells requires presentation of exogenous antigen. Nature (Lond.), 398: 77-80, 1999.
43. Corr, M., von Damm, A., Lee, D. J., and Tighe, H. In vivo priming by DNA injection occurs predominantly by antigen transfer. J. Immunol., 163: 4721-4727, 1999.
44. Gabrilovich, D. I., Corak, J., Ciernik, I. F., Kavanaugh, D., and Carbone, D. P. Decreased antigen presentation by dendritic cells in patients with breast cancer. Clin. Cancer Res., 3: 483-490, 1997.
45. + lymphocytes in the initiation of class I-restricted reactivity to a tumor/self peptide. Crit. Rev. Immunol., 18: 87-98, 1998.
46. Dittel, B. N., Visintin, I., Merchant, R. M., and Janeway, C. A., Jr. Presentation of the self antigen myelin basic protein by dendritic cells leads to experimental autoimmune encephalomyelitis. J. Immunol., 163: 32-39, 1999.
47. + T cells expressing endogenous T cell receptor chains protect myelin basic protein-specific transgenic mice from spontaneous autoimmune encephalomyelitis J. Exp. Med., 188: 1883-1894, 1998.
48. + T cells, are required for the development of experimental autoimmune gastritis. Immunology, 93: 405-408, 1998.
49. Kumar, V., Stellrecht, K., and Sercarz, E. Inactivalion of T cell receptor peptide-specific CD4 regulatory T cells induces chronic experimental autoimmune encephalomyelitis (EAE). J. Exp. Med. 184: 1609-1617, 1996.
50. Waisman, A., Ruiz, P. J., Hirschberg, D. L., Gelman, A., Oksenberg, J. R., Brocke, S., Mor, F., Cohen, I. R., and Steinman, L. Suppressive vaccination with DNA encoding a variable region gene of the T-cell receptor prevents autoimmune encephalomyelitis and activates Th2 immunity. Nat. Med., 2: 899-905, 1996.
51. Haqqi, T. M., Qu, X. M., Anthony, D., Ma, J., and Sy, M. S. Immunization with T cell receptor V β chain peptides deletes pathogenic T cells and prevents the induction of collagen-induced arthritis in mice. J. Clin. Investig., 97: 2849-2858, 1996.